🎓 Warm congrats to Elvin Maharramov @m-elvin.bsky.social on a successful PhD defense on the principles of designing #antibiotics with limited #resistance. A timely and elegant contribution to the field of #DrugDevelopment on how to design less resistance-prone antibiotics. More info below👇

Excited to share our collaborative work led by the Szilvia Juhasz and Mate Manczinger @matemanc.bsky.social labs: #cancer mutations converge into five protein-level “fingerprints” that shape tumor immune visibility. Mutation burden alone fails to predict #immunotherapy response! @molsystbiol.org

C > U mutations generate immunogenic peptides in SARS-CoV-2 @natcomms.nature.com @matemanc.bsky.social @csabapallab.bsky.social www.nature.com/articles/s41...

C > U mutations generate immunogenic peptides in SARS-CoV-2 APOBEC enzymes—key players of the innate immune system—induce mutations that become fixed in viral genomes and enhance immune recognition. nature.com/articles/s41... #COVID_19 #Immunology #virus #infectiousdiseases #vaccine #Genetics

A dual-target antibiotic strategy, combining membrane disruption with another cellular pathway, shows promise in reducing bacterial resistance, offering a new direction in combating antimicrobial resistance. doi.org/g855sh

We are looking for a postdoc in #EvolutionarySystemsBiology. Exciting science, amazing team, wonderful city! landrylab.ibis.ulaval.ca/research-opp... #evolution #synbio #systemsbiology #genomics

🚨 Our latest research in @naturecomms.bsky.social shows a promising strategy for less resistance-prone #antibiotics. For details, see the thread below and read the paper “Exploring the principles behind antibiotics with limited resistance” here: #MEvoSky www.nature.com/articles/s41...

Two recent studies led by 🇭🇺 @csabapallab.bsky.social find that resistance can develop against new 💊 antibiotics even before they are widely used, compromising their effectiveness from the start. #antibioticresistance #AMR

Alternative drug modalities/approaches are desperately needed to supplement the pipeline of antibiotics.

ESKAPE pathogens are outsmarting us. Our latest paper in @naturemicrobiol.bsky.social reveals alarming ease of resistance evolution to antibiotics in development. Collaborative work with @csabapallab.bsky.social‬ and Kintses Lab

💊🦠OUT NOW - comprehensive analysis of the propensity of ESKAPE pathogens to evolve resistance to new and in development antibiotics by Csaba Pal, Balint Kintses, Balazs Papp and colleagues. Dive in here... www.nature.com/articles/s41...

🚨 Excited to share that our new study, “ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro” is published in @naturemicrobiol.bsky.social. For details, see the 🧵below and read the paper here: www.nature.com/articles/s41...

Awesome! Many thanks ‪@thealexknapp.bsky.social‬ for spotlighting our recent work!

Thrilled to share our latest work, "Antibiotic candidates for Gram-positive bacterial infections induce multidrug resistance" in Science Translational Medicine! For details, see the thread below and read the paper here: www.science.org/doi/10.1126/...

Thrilled to share our latest work, "Antibiotic candidates for Gram-positive bacterial infections induce multidrug resistance" in Science Translational Medicine! For details, see the thread below and read the paper here: www.science.org/doi/10.1126/...

While writing papers and grants, we received many comments on the role of CNVs in antifungal resistance. We thought we should formally assess how important they are. Here is what we found. #AMR #fungi #evolution rdcu.be/d5rbN